Skip to main content
. 2020 Jan 6;111(2):561–570. doi: 10.1111/cas.14260

Table 3.

Number of patients with ≥grade 3 treatment‐related adverse events

  Grade 3
Nausea 1 (Level 3)
Hypokalemia 2 (Level 3)
Thrombocytopenia 1 (Level 3)
Lung infection 1 (Level 2)
Peripheral neuropathy 1 (Level 3)